Delivery Order SPE2DB22D3501-SPE2DB25FXK45
- Not listed
- The Defense Logistics Agency (DLA) awarded a Delivery Order valued at $14,887.74 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Prolia 60 mg/ml syringes. This non-set-aside, firm fixed price contract is scheduled for completion by August 20, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,350.56 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of September 15, 2025. This is a firm fixed price delivery order with no set-aside designation, issued competitively to the prime contractor. The contract represents a call against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $1 billion...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $67,829.29 to AmerisourceBergen Drug Corp for the supply of Prolia 60 mg/ml syringes. This firm fixed-price delivery order, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $14,539.96 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of September 8, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the pharmaceutical distributor's Corporate Office located in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with...
- The Defense Logistics Agency awarded a delivery order valued at $16,071.75 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $29,291.77 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Prolia 60 mg/ml syringes. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract carries no set-aside designation, indicating open...
- The Defense Logistics Agency awarded a delivery order valued at $32,625.43 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of August 20, 2025. This is a firm fixed-price, non-set-aside contract executed on August 19, 2025, with performance to take place at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/mL syringes, valued at $9,104.04 under firm fixed price terms. The award, issued on August 7, 2025, with completion targeted for August 8, 2025, represents a child delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Prolia 60 mg/mL syringes, valued at $11,629.70. This is a firm fixed price delivery order with an ultimate completion date of August 27, 2025, and represents a non-set-aside competitive award. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. As a child order under a larger...
- The Defense Logistics Agency awarded a $26,034.19 delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes under a firm fixed-price contract. The delivery order, issued on July 14, 2025, with an ultimate completion date of July 15, 2025, represents a competitively awarded non-set-aside procurement. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXK45Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,852.74 to AmerisourceBergen Drug Corp for the supply of Prolia 60 mg/ml syringes, with an ultimate completion date of September 19, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's comprehensive $1 billion IDC with DLA Troop Support Medical (contract SPE2DX, running through December 2026), which serves as a global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to military healthcare systems worldwide. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen maintains an extensive portfolio of federal contract awards covering specialty medications, brand-name and generic drugs, vaccines, and medical devices. The current delivery order for Prolia—a treatment for osteoporosis—reflects the company's role in supporting Defense Health Agency and broader military healthcare procurement needs through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.9k | 9/18/25 |